Skip to main content
SP5007,677.28+0.32%DOW53,577.40+0.30%NASDAQ26,151.30+0.66%BTC$78,623.00-1.29%ETH$2,446.81-1.94%GOLD$4,695.10+0.01%OIL$80.77-1.93%
Smart Investors Daily
Sign InSign Up Free
OC

NASDAQ · OCEA

Ocean Biomedical, Inc.

Healthcare · Biotechnology

$0.00

Down-$0.00 (-16.67%)

Updated Aug 26, 2026, 1:10 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.78M
P/E ratio
-0
Dividend yield
0.00%
52-week range
— – —
Volume
7.78K
Avg. volume
639.28K

Price performance

OCEA price history

1M range · 0 trading sessions · Daily adjusted prices

OCEA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest OCEA news

The latest Smart Investors Daily articles mentioning OCEA.

Stock researchCompany · Overview

OCEA research

Overview

Company profile and research snapshot.

Company profile

OCEAN BIOMEDICAL INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$18.87
Implied upside
—
Analysts
7
OCEA recent ratings
DateFirmRatingTarget
May 31, 2023Taglich BrothersSpeculative Buy—
Apr 27, 2023EF HuttonBuy—
Apr 13, 2023EF HuttonBuy—
Mar 16, 2023Fundamental Research Corp.Buy—
Mar 13, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 22, 2024

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical, Inc. received a notice from Nasdaq stating that it is not in compliance with the requirement to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024. The company is delayed in filing the report due to previously disclosed issues with its 2023 annual report. This could impact the company's Nasdaq listing.

GlobeNewswire Inc. · Oct 1, 2024

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical has published new research that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases. The research demonstrates the complex ways that CHI3L1 inhibits macrophage phagocytosis, providing a mechanistic explanation for the ability of CHI3L1 to stimulate immune checkpoint inhibitors and inhibit essential adaptive immune responses in cancer and COPD.

GlobeNewswire Inc. · Jun 5, 2024

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 - 8.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By